| Name | Title | Contact Details |
|---|---|---|
Jonathan Schantz |
Associate Director of R&D Operations | Profile |
Trevor Smith |
Vice President Preclinical R&D | Profile |
Rune Kjeken |
Executive Director, Research & Development | Profile |
Rune Kjeken |
Executive Director of Research & Development | Profile |
Kate Broderick |
Senior Vice President R&D | Profile |
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark`s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson`s disease.
BIND Therapueitics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.
BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin™, a remarkable biotechnology that leverages a small sample of a patient`s own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week.